Trusted Resources: Education
Scientific literature and patient education texts
Generation of DMBi002-A Human Induced Pluripotent Stem Cell Line From Patient With Spinal Muscular Atrophy Type 3
source: Stem cell research
year: 2021
authors: Andrysiak K,Martyniak A,Potulska-Chromik A,Kostera-Pruszczyk A,Stępniewski J,Dulak J
summary/abstract:Spinal Muscular Atrophy (SMA) is a genetic neuromuscular disease caused by mutations inSMN1 gene encoding survival motor neuron (SMN) protein. Lack of this protein leads to progressive loss of motor neurons and therefore to gradual loss of signal transmission between motor neurons and skeletal muscle cells. As a consequence, patients develop muscle atrophy and lose the ability to move independently, what is also related to problems with breathing and swallowing. Here, we describe the generation of human induced pluripotent stem cells (hiPSC) from peripheral blood mononuclear cells (PBMC) of adult SMA type 3 patient with a use of Sendai virus vectors.
organization: Department of Medical Biotechnology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Kraków, Poland.DOI: 10.1016/j.scr.2021.102563
read more
Related Content
-
Spinal Muscular Atrophy: OverviewWhat is spinal muscular atrophy (SMA)?Sp...
-
Managing Pregnancy in a Spinal Muscular Atrophy Type III Patient in Indonesia: A Case ReportSpinal muscular atrophy (SMA) is a genet...
-
Spinal Muscular Atrophy (SMA)Spinal muscular atrophy (SMA) is a genet...
-
Spinal Muscular Atrophy and TypesWhat is Spinal Muscular Atrophy?Spinal m...
-
Safety and Efficacy of Once-Daily Risdiplam in Type 2 and Non-Ambulant Type 3 Spinal Muscular Atrophy (SUNFISH Part ...Background: Risdiplam is an oral small m...
-
Once-Daily Risdiplam Beneficial in Patients With Types 2 and 3 SMA: LancetOnce-Daily Risdiplam is beneficial in pa...
-
Patient and Caregiver Treatment Preferences in Type 2 and Non-Ambulatory Type 3 Spinal Muscular Atrophy: A Discrete ...Background: Spinal muscular atrophy (SMA...